Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
REPL
REPL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
REPL News
Replimune Reports Q3 Earnings Beat Expectations
Feb 04 2026
seekingalpha
Alto Neuroscience and Others Under Investigation for Shareholder Claims
Jan 20 2026
Globenewswire
Replit Launches Natural Language App Development Feature, Enabling Rapid User Deployment
Jan 15 2026
Newsfilter
Replimune (REPL) and Upstart (UPST) See Significant Options Trading Volume Surge
Jan 05 2026
NASDAQ.COM
The Short List: Current Top 10 Most Shorted Stocks
Nov 26 2025
Benzinga
Opinion | Advances in Technology Are Turning the Tide in the Fight Against Cancer
Nov 16 2025
WSJ
Editorial | The FDA's Crisis Intensifies
Nov 06 2025
WSJ
Editorial | Will Clinical Trials Endure Under the New FDA?
Nov 05 2025
WSJ
Editorial | Uncertain Backing for the FDA's Biologics Evaluation
Nov 03 2025
WSJ
Major Stocks, Including Kimberly-Clark and Vertex, Decline in Monday's Pre-Market Trading
Nov 03 2025
Benzinga
BMO Capital Elevates Replimune Group Rating to Market Perform and Increases Price Target to $11
Nov 03 2025
Benzinga
Editorial | The Influencers at the FDA
Oct 27 2025
WSJ
Five Below Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Monday
Oct 27 2025
Benzinga
Significant Options Activity on Monday: UNH, REPL, CELC
Oct 20 2025
NASDAQ.COM
Monday's Major Stock Market Highlights: Morning News Summary!
Oct 20 2025
TipRanks
Leerink Partners Boosts Replimune Group Rating to Outperform and Increases Price Target to $13
Oct 20 2025
Benzinga
Show More News
